【佳学基因检测】基于深度学习的肺癌铁死亡相关基因特征的临床和生物学意义

肿瘤基因检测龙头企业国产

在高峰论坛中体会到《Comput Math Methods Med》在. 2022 Aug 25;2022:6495301.发表了一篇题目为《基于深度学习的肺癌铁死亡相关基因特征的临床和生物学意义》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Xiaosong Yang, Xuanjian Hu, Na Guo等完成。促进了肿瘤的正确治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及正确治疗临床研究内容关键词：

肿瘤靶向治疗基因检测临床应用结果

酰基辅酶A合成酶长链家族成员4（ACSL4）与肿瘤的发生有关，并与铁死亡过程有关。深度学习已应用于医疗保健的许多领域，包括影像诊断、数字病理学、癌症分类和转移预测。尽管如此，ACSL4 的表达水平及其在非小细胞肺癌 (NSCLC) 中的预测意义目前尚不清楚。在 Oncomine 和 TCGA 数据库的帮助下，预测了 NSCLC 中的 ACSL4 mRNA 表达及其与 NSCLC 预后的联系。通过进行实时 PCR，我们检测了人类 NSCLC 样本中存在的 ACSL4 表达水平。使用 Kaplan-Meier 曲线分析了 ACSL4 在 NSCLC 中的诊断以及预后意义。为了评估 ACSL4 对 NSCLC 细胞系中铁死亡的影响，本研究中使用了一种铁死亡诱导剂，即erastin。在 NSCLC 组织中，ACSL4 表达水平显着降低（p < 0.001），这与对 Oncomine 和 TCGA 数据库的调查结果一致。之后，免疫组织化学分析的结果显示，与正常样本相比，NSCLC样本中的ACSL4染色减弱。结果表明，ACSL4 的差异表达与癌症的分期、吸烟行为和淋巴结转移的状态有很大关系（所有 p < 0.001）。根据生存分析结果，在 ACSL4 表达升高的 NSCLC 患者中，无反复生存期 和 总生存期 均有利。通过基因转染上调 ACSL4 可以重新建立癌细胞中的铁死亡敏感性。从机制上讲，蛋白质泛素化可以在 ACSL4 诱导的铁死亡中发挥显着的作用。 ACSL4 在铁死亡中具有作为贡献者和监测者的功能，在 NSCLC 中显示下调。这一发现表明 ACSL4 可能作为一种有用的诊断和预后生物学标志物发挥作用，也可能被认为是 NSCLC 的一种新的可能治疗靶点。

肿瘤发生与反复转移国际数据库描述：

Acyl-CoA synthetase long-chain family member 4 (ACSL4) has been linked to the occurrence of tumors and is implicated in the ferroptosis process. Deep learning has been applied to many areas in health care, including imaging diagnosis, digital pathology, classification of cancer, and prediction of metastasis. Nonetheless, neither the level of ACSL4 expression nor its predictive significance in non-small-cell lung cancer (NSCLC) is well understood at this time. Predictions of the ACSL4 mRNA expressions in NSCLC and its link to NSCLC prognosis were made with the aid of the Oncomine and TCGA databases. By performing real-time PCR, we detected the levels of ACSL4 expression that were present in human NSCLC samples. Analyses of the diagnostic, as well as the prognostic significance of ACSL4 in NSCLC, were performed with the use of Kaplan-Meier curves. To assess the influence of ACSL4 on ferroptosis in NSCLC cell lines, an inducer of ferroptosis, namely, erastin, was utilized in this study. In NSCLC tissues, there was a substantial decrease in the level of ACSL4 expression (p < 0.001), and this was in line with the findings of the inquiry into the Oncomine and TCGA databases. After that, the findings of the immunohistochemistry analysis revealed that the ACSL4 staining was weakened in NSCLC samples in contrast with the normal samples. It was shown that the differential expression of ACSL4 was substantially linked to the stages of cancer, smoking behaviors, and the status of nodal metastases (all p < 0.001). According to the findings of the survival analysis, both RFS and OS were favorable among NSCLC patients who had elevated expression of ACSL4. The ferroptosis sensitization in cancer cells may be reestablished with upregulation of ACSL4 through gene transfection. Mechanistically, protein ubiquitination could perform a remarkable function in ACSL4-induced ferroptosis. ACSL4, which has a function in ferroptosis as both a contributor and monitor, was shown to be downregulated in NSCLC. This finding suggests that ACSL4 might function as a helpful diagnostic and prognostic biological marker and might also be considered a novel possible treatment target for NSCLC.